FGFR2 and neoplasm: Patients with FGFR2 in-frame fusions, frame unknown REs and IGR REs—independently of FGFR2amp status—showed strong tumour responses to pemigatinib therapy (Fig. 5a), resulting in objective responses or stable disease in 80–100% of patients, irrespective of the diagnosed FGFR2 RE type (Fig. 5b).